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Abstract: The Wnt/-catenin signaling pathway is abnormally activated in most colorectal 
cancers and in a proportion of other neoplasias. This activation initiates or contributes to 
carcinogenesis by regulating the expression of a large number of genes in tumor cells. The 
active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibits Wnt/-catenin 
signaling by several mechanisms at different points along the pathway. Additionally, 
paracrine actions of 1,25(OH)2D3 on stromal cells may also repress this pathway in 
neighbouring tumor cells. Here we review the molecular basis for the various mechanisms 
by which 1,25(OH)2D3 antagonizes Wnt/-catenin signaling, preferentially in human colon 
carcinoma cells, and the consequences of this inhibition for the phenotype and proliferation 
rate. The effect of the vitamin D system on Wnt/-catenin signaling and tumor growth in 
animal models will also be commented in detail. Finally, we revise existing data on the 
relation between vitamin D receptor expression and vitamin D status and the expression of 
Wnt/-catenin pathway genes and targets in cancer patients. 
Keywords: vitamin D; 1,25-dihydroxyvitamin D3; Wnt; -catenin; colon cancer; vitamin 
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1. Introduction 
Vitamin D3 is obtained from the diet or mainly synthesized in the skin upon UV-B solar radiation. 
Subsequent hydroxylation in the liver, kidney and other tissues renders 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3, calcitriol), the most active vitamin D metabolite. 1,25(OH)2D3 is a pleiotropic hormone 
with many regulatory effects. In addition to its classical action on intestinal calcium absorption and 
bone biology, 1,25(OH)2D3 inhibits proliferation, migration and anchorage-independent growth, and 
promotes differentiation of a variety of cultured cancer cells [1–3]. Consistently, numerous studies 
have shown tumor-suppressive actions (anti-angiogenic, anti-invasive, antimetastatic) in animal 
models [3], and epidemiological data suggest a protective role of vitamin D against several neoplasias, 
particularly colorectal cancer [4,5]. 
1,25(OH)2D3 regulates gene expression via binding to the vitamin D receptor (VDR), a member of 
the superfamily of nuclear receptors that is expressed in many normal and cancer cell types. VDR 
heterodimerizes with Retinoid X Receptor (RXR) and acts as a ligand-regulated transcription factor 
modulating the transcription rate of hundreds of target genes [1,6,7]. VDR also mediates rapid,  
non-genomic effects of 1,25(OH)2D3 on membrane and cytosolic signaling molecules (ion channels, 
kinases, phosphatases) [8]. These extra-nuclear effects are sometimes required for the gene regulatory 
activity of 1,25(OH)2D3/VDR complexes [9]. 
Human Wnts are a group of 19 secreted proteins that control proliferation, survival, migration, 
differentiation, and/or lineage decisions in many cell types during development and adult life [10]. To 
this end, Wnts activate a series of signaling pathways upon binding to specific membrane receptors: 
the Wnt/-catenin or canonical pathway and several -catenin-independent non-canonical pathways. 
Activation of a particular Wnt pathway depends on the individual Wnt ligand and the repertoire of 
receptors expressed in the target cell [11,12]. 
The Wnt/β-catenin pathway controls the intracellular levels of β-catenin. In the absence of Wnt 
signals, free β-catenin is targeted by a cytoplasmic protein complex known as the β-catenin destruction 
complex, which promotes its phosphorylation, ubiquitination and degradation by the proteasome. 
Components of this complex include the tumor suppressors AXIN and APC and the protein kinases 
CK1 and GSK3β. Wnt binding to membrane heterodimeric receptors (Frizzled and LRP5/6) results in 
inhibition of destruction complexes and subsequent accumulation of unphosphorylated β-catenin 
molecules in the cytoplasm, a part of which enters the nucleus and behaves as a co-activator of 
LEF/TCF transcription factors. β-catenin/LEF/TCF target genes encode proteins that are involved in 
most if not all cellular processes including proliferation, cell cycle regulation, metabolism, migration, 
lineage commitment, and differentiation [11,13]. 
The Wnt/-catenin pathway is mainly active during embryonic development, although it also 
contributes to homeostasis in different tissues in adult life. Importantly, its abnormal activation in a 
series of epithelia is linked to generation or progression of carcinomas of the colon, breast, liver, 
pancreas and others. In particular, activation of the Wnt/-catenin pathway is the initial event in a high 
proportion of colorectal carcinomas [11,14], and recent massive sequencing has shown that over 94% 
of colon tumors harbor mutations in one or more genes of the pathway [15]. Importantly, alterations in 
other genes and/or pathways increase the level of activation of Wnt/-catenin signaling in colon cancer 
cells. Thus, crosstalk between hepatocyte growth factor (HGF)/c-MET and β-catenin signaling sustains 
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and increases the invasive properties of colorectal cancer cells [16]. Moreover, activation of Wnt 
signaling in colon cancer stem cells appears to require a co-stimulatory signal involving c-MET 
activation by stromal-derived HGF [17,18]. Also, mutant K-RAS may enhance β-catenin/TCF-dependent 
transcription in APC mutant K-RAS-dependent colon cancer cells by a mechanism involving bone 
morphogenetic protein (BMP)-7 secretion and autocrine signaling, leading to activation of  
TGF-β-activated kinase (TAK1) [19]. 
Mutations in the tumor suppressor APC gene are by far the most frequent insult leading to 
constitutive activation of the Wnt/β-catenin pathway in colorectal cancer. However, in a small 
percentage of cases, mutations in AXIN or in the CTNNB1/β-catenin proto-oncogene itself have also 
been found. In addition, 20%–40% of hepatocellular carcinomas present mutations in CTNNB1/β-catenin 
or AXIN [20–22]. By contrast, overproduction of Wnt factors and/or repression of pathway inhibitors 
(SFRP, DKK-1...) have an important contribution in a proportion of hepatocellular carcinomas and 
other cancers such as breast or pancreas [22]. 
The Wnt/-catenin pathway cannot be considered intrinsically tumorigenic, as it promotes 
differentiation of some cell types such as osteoblasts, myoblasts and neural precursors [23–26]. 
Moreover, Wnt/-catenin signaling has controversial effects on melanoma [27] and its activation 
seems to collaborate with B-RAF inhibitors to impede melanoma progression [28]. Why the aberrant 
activation of this pathway in the colonic epithelium is so important for the initiation and progression of 
colon cancer is unclear.  
Non-canonical Wnt pathways include the so-called planar cell polarity pathway which involves 
activation of Rho small GTPases and JNK and ROCK kinases, and the calcium pathway with 
activation of protein kinase C, calmodulin kinase, calcineurin and NFAT transcription factor [29,30]. 
The role of non-canonical Wnt pathways in cancer is unclear. Several authors suggest that they 
antagonize the tumorigenic effects of Wnt/-catenin signaling [31]. Others propose that while this may 
occur at early stages of carcinogenesis, non-canonical pathways would contribute at later stages [32]. 
2. Antagonism of Wnt/-Catenin Signaling by 1,25(OH)2D3 
The first evidences of crosstalk between nuclear hormone receptors (NHR) and Wnt/β-catenin 
signaling appeared the late 1990s [33] and early 2000s [34,35]. Since these initial discoveries, several 
laboratories have demonstrated functional interactions between both pathways underlying important 
biological and pathological processes. The nature of this crosstalk is complex and not fully understood, 
as the functional outcome depends largely upon cellular context [36,37]. In general, β-catenin 
potentiates NHR activity while liganded NHRs attenuate or even repress β-catenin signaling, although 
there are important exceptions to this rule. Molecular mechanisms underlying this crosstalk are also 
abundant and include, but are not limited to, physical interaction between NHRs and β-catenin or 
TCF/LEF transcription factors. In this review we focus on the crosstalk between VDR and Wnt/β-catenin 
signaling in cancer, with special emphasis on colon cancer, and the functional outcome of this interaction. 
2.1. Studies in Cultured Cells 
Results from our group showed that 1,25(OH)2D3 antagonizes the Wnt/-catenin pathway in human 
colon cancer cells by three main mechanisms (Figure 1). First, it induces VDR/-catenin interaction, 
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thus reducing the amount of -catenin bound to TCF [35]. Second, 1,25(OH)2D3 induces E-cadherin 
expression, leading to β-catenin nuclear export and relocation to the adherens junctions at the plasma 
membrane [35]. And third, 1,25(OH)2D3 induces the expression of Dickkopf (DKK)-1, an extracellular 
inhibitor of Wnt signaling [38]. As a result, we have found that 1,25(OH)2D3 inhibits the expression of 
several -catenin/TCF target genes such as c-MYC, TCF1, LEF1, AXIN2, PPAR, CD44, ENC1 and 
EPHB2 in human colon cancer cells [35,39,40]. These mechanisms of Wnt/-catenin antagonism are 
completely dependent on VDR expression, as they are not observed in VDR-negative human colon 
cancer cells (SW480-R and SW620) or in VDR-positive cells (SW480-ADH) in which VDR expression 
has been repressed by Snail1 or Snail2 overexpression or by shRNA technology [35,38–42]. 
VDR/-catenin interaction was later confirmed by Shah et al. in other cell types [43]. In addition, 
these authors characterized the domains responsible for the interaction: the C-terminal region of  
β-catenin and the activator function-2 domain of VDR. Interestingly, while 1,25(OH)2D3 antagonizes  
-catenin/TCF transcriptional activity, -catenin potentiates that of 1,25(OH)2D3/VDR [35,43,44]. 
Recently, Egan et al. have reported that wild-type APC enhances VDR/-catenin interaction and that 
the VDR ligand lithocholic acid also promotes the interaction, albeit to a lesser extent than 
1,25(OH)2D3 [45]. 
The contribution of E-cadherin induction to Wnt/-catenin inhibition by 1,25(OH)2D3 seems to be 
cell-type specific, as the antagonism has also been observed in E-cadherin-negative cell lines such us 
LS174T [35]. Supporting the relation between E-cadherin induction and Wnt/-catenin antagonism, 
we have shown that activation of the RhoA small GTPase and induction of JMJD3 histone 
demethylase contribute to both the induction of E-cadherin and the inhibition of -catenin/TCF 
transcriptional activity by 1,25(OH)2D3 [9,46]. In addition to human colon cancer cells, Xu et al. 
observed that 1,25(OH)2D3 induces E-cadherin expression and inhibits -catenin/TCF transcriptional 
activity in rat Rama-37 mammary epithelial cells [47]. 
DKK-1 belongs to the Dickkopf gene family that encodes secreted proteins that bind to LRP5/6 and 
function as extracellular inhibitors of Wnt/β-catenin signaling. DKK-1 binding to LRP5/6 blocks  
Wnt-Frizzled-LRP5/6 interaction and also induces the formation of a complex with another DKK 
receptor named Kremen that leads to LRP5/6 endocytosis [48,49]. As most colon tumors have 
mutations that render a constitutively active Wnt/β-catenin pathway, the importance of DKK-1 
induction for Wnt/-catenin antagonism by 1,25(OH)2D3 is unclear. However, DKK-1 seems to have 
antitumor effects independent of β-catenin/TCF transcriptional inhibition, as DKK-1 overexpression in 
APC-mutant colon cancer cells decreases colony formation capacity in vitro and tumor growth in 
immunodeficient mice [50].  
DKK-4 is a weaker inhibitor of Wnt/β-catenin signaling than DKK-1. Surprisingly, we found that 
1,25(OH)2D3 inhibits DKK-4 expression in human colon and breast cancer cells and that DKK-4 
overexpression in human colon cancer cells increases their migratory, invasive and angiogenic 
capacities [51]. These results suggest that the inhibition of DKK-4 by 1,25(OH)2D3 may contribute to 
the antitumor effects of 1,25(OH)2D3 in colon cancer. 
The use of 1,25(OH)2D3 in cancer prevention and therapy is restricted by its hypercalcemic effects 
at therapeutic doses. This has led to the development of several 1,25(OH)2D3 analogues that retain the 
antitumor actions but lack the hypercalcemic effects of 1,25(OH)2D3. We have found that 1,25(OH)2D3 
analogues EB1089, KH1060, MC903, WU515, CD578 and WY1113 inhibit -catenin/TCF transcriptional 
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activity in a similar or even greater extent than 1,25(OH)2D3 in human colon cancer cells [35,52]. In 
addition, Xu et al. obtained similar results with the QW and BTW analogues in colon and breast  
cancer cells [47]. 
Notably, other authors have reported different mechanisms of crosstalk between 1,25(OH)2D3 and 
Wnt/-catenin pathway (Figure 1). Beildeck et al. found that 1,25(OH)2D3 induces the expression of 
TCF4 in several human colon cancer cell lines by a VDR-dependent indirect mechanism [53]. 
However, the consequences of TCF4 induction for -catenin/TCF transcriptional activity are not clear. 
The authors proposed a model whereby in normal cells, or in tumor cells that do not have nuclear -
catenin, TCF4 upregulation would enhance the repression of -catenin/TCF target genes. In line with 
this, it has been reported that TCF4 inhibits growth of colon cancer cells [54]. Thus, the induction of 
TCF4 expression by 1,25(OH)2D3 may have a protective role in colon cancer. 
Kaler et al. have reported a role of tumor stroma in the interplay between Wnt/-catenin signaling 
and 1,25(OH)2D3 [55]. They found that tumor cells induce the release of interleukin (IL)-1 by THP-1 
macrophages. In turn, macrophage-derived IL-1 inhibits GSK3 activity in colon carcinoma cells, 
leading to -catenin protein stabilization and increasing -catenin/TCF transcriptional activity. This 
mechanism is repressed by 1,25(OH)2D3 through the inhibition of IL-1 production in THP-1 cells 
and, if functional in tumor-associated macrophages, it may be another way to interfere with  
Wnt/-catenin signaling in vivo.  
Interestingly, Meyer et al. have recently identified VDR/RXR and TCF4/-catenin cistromes using 
chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-Seq) in a human 
colon cancer cell line [56]. They found that VDR/RXR co-occupied 1,674 sites upon 1,25(OH)2D3 
treatment, most of them distal to transcription start sites. ChIP-Seq analysis also revealed 828  
-catenin and 3,161 TCF4 binding sites: after treatment with 1,25(OH)2D3 these figures decreased 
slightly for the former, but increased significantly for the latter. Examination of the overlap between 
TCF4/-catenin and VDR/RXR cistromes indicates that the two heterodimers colocalize at 74 sites 
located near a limited set of genes that included c-FOS and c-MYC. These data support a direct action 
of both complexes at certain gene loci [56]. 
c-MYC is a key regulator of cell cycle progression and its expression is frequently elevated or 
deregulated in human cancer [57,58]. In addition, mutational and integrative analyses have emphasized 
the critical role of this proto-oncogene in colorectal cancer [15]. 1,25(OH)2D3 has been reported to 
downregulate c-MYC expression by two mechanisms. On the one hand, ligand-activated VDR directly 
represses c-MYC expression by binding two vitamin D response elements (VDRE) in the c-MYC 
promoter [59]. On the other, 1,25(OH)2D3 interferes with β-catenin/TCF-induced c-MYC transcription 
mediated by Wnt responsive elements (WRE) in the proto-oncogene promoter [60]. Interestingly, 
Salehi-Tabar et al. have recently demonstrated that 1,25(OH)2D3-dependent suppression of β-catenin 
function in a head and neck squamous cell carcinoma cell line is largely responsible for the inhibition 
of c-MYC RNA expression [61]. Moreover, they also showed that 1,25(OH)2D3 enhanced the 
expression of the c-MYC antagonist partner Mad/Mxd1 [61], further contributing to the inhibition of  
c-MYC target genes. 
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Figure 1. Schematic representation of the mechanisms of Wnt/-catenin pathway 
repression by 1,25(OH)2D3 in human colon carcinoma cells. (a) Wnt/-catenin pathway is 
activated by mutation of APC, CTNNB1/-catenin or AXIN genes, or by deregulated 
signaling from Wnt plasma membrane receptors. These alterations cause accumulation of 
-catenin protein in the cytoplasm and nucleus and transcription of its target genes;  
(b) 1,25(OH)2D3 inhibits -catenin/TCF transcriptional activity in colon carcinoma cells by 
several mechanisms. It promotes VDR/-catenin binding, thus reducing the amount of  
-catenin bound to TCF (1); it induces the expression of CDH1 gene coding for E-cadherin, 
which sequesters -catenin at the plasma membrane adherens junctions (2); and it enhances 
the expression of the extracellular Wnt inhibitor DKK-1 (3) and of TCF4 (4). Additional 
paracrine mechanisms of antagonism have been proposed.  
 
Although mutations in APC, AXIN or CTNNB1/-catenin genes in breast cancer are rare, the  
Wnt/-catenin pathway may be active in a proportion of these carcinomas according to the 
accumulation of nuclear -catenin protein observed, particularly in the triple-negative and basal-like 
subtypes, which are highly aggressive and of poor prognosis [62,63]. Moreover, recent data indicate 
that WNT10B induces transcriptionally active -catenin in human triple-negative breast cancers and 
predicts survival-outcome of patients with these two types of tumors [64]. Interestingly, 1,25(OH)2D3 
regulates the phenotype of cultured human breast cancer cells by modulating the level and localization 
of cytoskeletal and adhesion proteins. Among them, 1,25(OH)2D3 represses the expression of  
P-cadherin, smooth muscle -actin and 6- and 4-integrins that are myoepithelial/basal markers [65]. 
In line with this, Vdr-deficient mice express abnormally high levels of P-cadherin and smooth muscle 
-actin in the mammary gland [65]. These data suggest that 1,25(OH)2D3 may protect against the 
triple-negative and basal-like breast cancers that are associated with poor prognosis, perhaps via the 
inhibition of the Wnt/-catenin pathway. 
Remarkably, the antagonism of Wnt/-catenin signaling by the 1,25(OH)2D3 analogue paricalcitol 
has also been observed in other cellular systems unrelated to cancer such as vascular smooth muscle 
cells and renal podocytes [66,67]. 
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2.2. Studies in Animal Models 
Data from several types of studies using experimental animals support a protective and therapeutic 
effect of 1,25(OH)2D3 against several neoplasias [3,68,69].  
Human cancer cells injected subcutaneously into immunosuppressed mice (xenografts) are 
commonly used as an in vivo approach in cancer research. Numerous studies have shown that 
1,25(OH)2D3 and many analogues significantly reduce the growth of xenografts generated by tumor 
cells derived from several types of cancers [68,69]. We found that the 1,25(OH)2D3 analogue EB1089 
inhibits the growth of xenografts generated by SW480-ADH human colon cancer cells. Remarkably, 
this effect is associated with induction of E-cadherin and DKK-1 expression, -catenin nuclear export 
and inhibition of the expression of the -catenin/TCF target gene ENC1 in the xenografts [38,39,41]. 
Similar results were obtained when chemical carcinogens (azoxymethane or azoxymethane plus 
dextran sodium sulphate) were used to induce colon tumors in mice or rats. Several studies showed 
that tumor incidence in these models decreases following treatment with 1,25(OH)2D3 or several 
analogues [68]. In addition, Bissonnette’s group found that this antitumor action of 1,25(OH)2D3 is 
accompanied by the induction of E-cadherin expression and the repression of the -catenin/TCF target 
genes c-Myc and Ccnd1/Cyclin D1 in the colonic crypts and tumors of these animals [70,71]. 
Apc
min/+
 mice are commonly used animal model for intestinal cancer. They harbour a germ line 
inactivating mutation in one Apc allele and spontaneously develop multiple intestinal neoplasias at 
approximately three months of age [72]. This phenotype is due to the spontaneous mutation of the 
remaining Apc allele (loss of heterozygosity) and the consequent activation of the Wnt/-catenin 
pathway. Huerta et al. found that both 1,25(OH)2D3 and the 1,25(OH)2-16-ene-19-nor-24-oxo-D3 
analogue reduce tumor load (the sum of all polyp areas) along the entire gastrointestinal tract of 
Apc
min/+
 mice [73]. Xu et al. confirmed these results and showed that treatment with 1,25(OH)2D3 or 
two of its analogues increases E-cadherin expression, reduces nuclear -catenin levels and inhibits the 
expression of the -catenin/TCF target genes c-Myc and Tcf1 in the small intestine and colon of these 
mice [74]. However, Irving et al. did not find any effect of two 1,25(OH)2D3 analogues on the growth 
rate of colonic tumors developed in Apc
min/+
 mice treated with the tumor inducer dextran sodium 
sulphate. As mentioned by the authors, the length of treatment with the 1,25(OH)2D3 analogues or the 
putative loss of Vdr expression in the tumors might be the cause of the discrepancy with previous 
studies [75]. 
Several studies indicate that a Western-style diet that is high in fat and low in calcium and vitamin 
D increases the incidence of spontaneous intestinal tumors in normal mice and dramatically accelerates 
tumor formation in Apc
min/+
 mice and in other animal models for intestinal cancer [76]. In addition, this 
effect is reversed if the Western-style diet is supplemented in calcium and vitamin D [76]. Yang et al. 
used transcriptomic analyses to characterize the changes induced by the Western-style diet in colon 
epithelial cells of normal mice. They found that Wnt signaling is one of the functional categories that 
are significantly enriched among the genes whose expression is altered by Western-style diet and 
reversed to normal by calcium and vitamin D supplementation. These genes include those coding for 
-catenin and for the Wnt receptors Frizzled-2 and -10 [76,77]. Similarly, Wang et al. observed that 
calcium and vitamin D supplementation abrogates the increase of -catenin/TCF transcriptional 
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activity and of Frizzled-5 and Ephb2 expression promoted by Western-style diet in intestinal villi and 
colon crypt cells of normal mice [78]. 
Genetically-modified mice have also been used to analyze the effects of VDR on carcinogenesis. 
Vdr-deficient mice do not show an increase in spontaneous cancer incidence but are more predisposed 
to oncogene- or carcinogen-induced breast and skin cancer and leukemia [79]. In the distal colon, these 
animals display hyperproliferation and an increased rate of DNA damage by oxidative stress [80,81]. 
Thus, two teams attempted to decipher the effects of Vdr gene deletion on intestinal tumorigenesis by 
generating Apc
min/+
Vdr
−/−
 mice [40,82]. No differences were found in the number of small intestinal 
and colonic tumors. However, significantly increased tumor load and number of colonic aberrant crypt 
foci (premalignant lesions) were observed in Apc
min/+
Vdr
−/−
 mice as compared to Apc
min/+
Vdr
+/+
. 
Remarkably, the lesions of Apc
min/+
Vdr
−/−
 mice showed higher -catenin nuclear levels and expression 
of its targets genes Ccnd1/Cyclin D1 and Lef1 than those of Apc
min/+
Vdr
+/+
 mice, suggesting that Vdr 
deletion promotes intestinal tumor growth through the activation of the Wnt/-catenin pathway [40,82]. 
2.3. Studies in Patients 
Garland and Garland were the first to suggest that vitamin D deficiency may explain the higher 
colon cancer mortality rates found in latitudes with low solar radiation in USA [83]. Since then, 
several epidemiological studies have shown that incidence and/or risk of mortality of several types of 
cancer (particularly colon and breast) increases in people less exposed to sunlight or UV-B radiation, 
with low vitamin D dietary intake, or with low 25-hydroxyvitamin D serum levels [3,84]. Few cancer 
intervention clinical trials using vitamin D compounds for prevention or treatment have been 
completed in humans. Furthermore, the results obtained have been inconclusive, inconsistent or 
contradictory [3,85]. Thus, to establish a cause-effect relationship between vitamin D and cancer, it is 
necessary to perform new large-scale and well-designed clinical studies with cancer as the primary 
pre-specified outcome [3,85]. 
At the molecular level, Ahearn et al. conducted a randomized, double-blinded, placebo-controlled,  
2 × 2 factorial clinical trial to analyze the effect that daily supplementation of sporadic colorectal 
adenoma patients with vitamin D (800 IU) and/or elemental calcium (2 g) for 6 months has on the 
expression of APC, E-cadherin and -catenin in crypts of the normal appearing rectal mucosa [86]. 
Vitamin D or calcium supplementation increased the expression of APC and reduced that of -catenin 
in the differentiation zone of the crypt (the upper 40% of the crypt), which led to an increased  
APC/-catenin ratio. The supplementation only with vitamin D also induced E-cadherin expression in 
the same region. These results support those found in cultured cells and animal models and indicate 
that vitamin D can modify the expression of genes related to Wnt/-catenin signaling in humans in 
directions hypothesized to inhibit colon cancer [86]. 
VDR is expressed in the normal colon and upregulated at early stages of colon tumorigenesis 
(polyps, adenomas), whereas it decreases at advanced stages (carcinomas) [87–90]. Accordingly, VDR 
expression is associated with high tumor differentiation, absence of node involvement, and good 
prognosis in colon cancer [91,92]. These data suggest that advanced colon tumors with low VDR 
expression will probably be unresponsive to therapy with 1,25(OH)2D3 or its analogues. Our group 
found that the transcription factors Snail1 and Snail2 repress VDR expression and block the 
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antitumoral actions of 1,25(OH)2D3 in cultured colon cancer cells and in xenografted mice, including 
the inhibition of Wnt/-catenin signaling. In addition, VDR RNA expression in colon tumors inversely 
correlates with that of SNAIL1 and SNAIL2, suggesting that these transcription factors are responsible 
for the downregulation of VDR found in colon cancer [39,41,42,84,93,94]. Interestingly, Snail1 
protein levels and activity are induced by canonical Wnt signaling [95–98], which may constitute a 
mechanism to bypass the inhibitory effect of 1,25(OH)2D3 on this pathway. In addition to colon 
cancer, VDR downregulation by Snail factors has been also observed in osteoblasts, osteosarcoma, 
breast cancer and renal cells [99–102].  
E-cadherin expression is lost during the progression of several types of carcinomas and its 
downregulation is frequently associated with the acquisition of invasive and metastatic properties by 
tumor cells. Thus, it is considered an invasion-suppressor gene [103,104]. According to data from 
cultured cells and animal models, we found a significant direct correlation between VDR and  
CDH1/E-cadherin RNA levels in human colon tumors, suggesting that VDR/1,25(OH)2D3 may 
contribute to the restoration of normal E-cadherin levels in human colon cancer [93,105]. 
Our group
 
reported that DKK-1 expression is frequently downregulated in human colon cancer, 
which suggests that DKK-1 may act as a tumor suppressor gene in this neoplasia [106]. DKK-1 
downregulation is due to promoter methylation in 24% of advanced
 colon tumors (Dukes’ stages C  
and D) [50]. Thus, the induction of DKK-1 expression by 1,25(OH)2D3 found in cultured cells and 
animal models may contribute to restore DKK-1 expression and antitumor effects in human colon 
cancer. Accordingly, we found a significant direct correlation between VDR and DKK-1 RNA expression 
in tumor biopsies from colon cancer patients [38], and Rawson et al. have recently reported that 
dietary vitamin D intake was negatively associated with DKK-1 promoter methylation in a large cohort 
of human colorectal cancer patients [107]. These results suggest that the extracellular inhibition of 
Wnt/-catenin signaling may contribute to the effect of 1,25(OH)2D3 against colon carcinogenesis. 
We and others found that DKK-4 is overexpressed in human colon tumors and in colon samples 
from patients with inflammatory bowel disease [51,108,109]. Interestingly, our group also observed a 
significant inverse correlation between VDR and DKK-4 RNA levels in human colorectal tumors, 
suggesting that the regulation of DKK-4 observed in cell lines also occurs in patients [51]. 
3. Cooperation between VDR and Wnt/-Catenin Signaling 
Although 1,25(OH)2D3 inhibits -catenin/TCF transcriptional activity in colon and other cancer 
cells, the upregulation of the Wnt/-catenin pathway by either ligand-activated or unliganded VDR has 
been described in osteoblasts and keratinocytes, where it promotes bone formation and hair follicle 
differentiation, respectively. Thus, the interplay between Wnt/-catenin pathway and 1,25(OH)2D3/VDR 
seems to depend on the cell or tissue type. 
Wnt signaling promotes the differentiation of bone marrow-derived mesenchymal stem cells to 
bone while it represses their differentiation to other cell types, such as adipocytes [110,111]. Some 
1,25(OH)2D3 effects in bone are similar to those of Wnt, suggesting a crosstalk between both 
pathways. Indeed, 1,25(OH)2D3 induces the expression of the Wnt co-receptor Lrp5 in mouse 
osteoblasts [112,113], while represses that of the Wnt inhibitors Dkk-1 and Sfrp2 in mouse bone 
marrow-derived mesenchymal stem cells [114]. These effects support a role of 1,25(OH)2D3 
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stimulating Wnt signaling in normal bone. However, the interplay between these two pathways seems 
to change in tumor tissue, as it has been reported that 1,25(OH)2D3 inhibits Wnt/-catenin signaling in 
SaOS2 osteosarcoma cells [102]. 
Ligand-independent actions of VDR on Wnt canonical signaling have also been reported. In the 
skin, absence of Vdr, but not of 1,25(OH)2D3, results in alopecia in mice [115], and two independent 
groups have demonstrated that this is due, at least in part, to impaired Wnt/-catenin signaling in 
keratinocytes [116,117]. In this regard, Pálmer et al. have shown that VDR is a Wnt effector and that 
β-catenin behaves as a VDR co-activator in the skin to induce transcription of genes associated with 
differentiation of hair follicle lineages [117]. Although this effect is largely 1,25(OH)2D3-independent, it is 
enhanced by the hormone. More recently, Luderer et al. have reported a direct interaction between 
VDR and LEF1 that is independent of both ligand and β-catenin, and that is required for normal 
canonical Wnt signaling in keratinocytes [118]. Interestingly, Lef1 knock-out mice develop alopecia at 
an early age [119] and transgenic mice expressing a dominant negative Lef1 in keratinocytes also show 
a phenotype that resembles that of Vdr
−/−
 mice [120]. Therefore, although the in vivo significance of 
the VDR-LEF1 interaction is not yet clear, it may contribute to at least some of the ligand-independent 
effects of VDR in the skin. Similarly to what happens in bone, this interplay seems to change in the 
tumoral context. The development of trichofolliculomas (benign hair follicle tumors) induced by 
prolonged activation of -catenin in the skin is inhibited by the 1,25(OH)2D3 analogue EB1089 [117]. 
In addition, undifferentiated tumors resembling basal cell carcinomas instead of trichofolliculomas are 
developed by -catenin activation in Vdr−/− mice [117]. Accordingly, keratinocytes lacking VDR 
present decreased E-cadherin expression, increased -catenin/TCF transcriptional activity, and a 
higher proliferation rate; whereas VDR overexpression or 1,25(OH)2D3 treatment has the opposite 
effect [121,122]. These results suggest that 1,25(OH)2D3/VDR suppresses epidermal tumor formation 
by limiting the hyperproliferative actions of -catenin in the skin. Surprisingly, epidermal -catenin 
ablation cannot reduce the increased number of UVB-induced tumors developed by epidermis-specific 
Vdr knock-out mice, suggesting that VDR has -catenin-independent anticancer functions in  
this model [122]. 
4. Conclusions 
Evidence from a wide series of biological systems shows that inhibition of Wnt/-catenin pathway 
is one of the mechanisms of vitamin D action. Wnt/-catenin signaling has many important regulatory 
effects in the organism and thus, it is conceivable that the role of vitamin D is the control of an 
adequate level of activation of the route in each tissue and developmental stage. This most probably 
includes the antagonism of Wnt/-catenin signaling in colorectal and possibly other carcinomas in 
which this pathway has a crucial oncogenic action. The finding that the repressive action of vitamin D 
takes places at different levels of the Wnt/-catenin pathway, by distinct mechanisms, and in several 
cell types reinforces the importance of this regulatory action. 
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